REPURCHASE OF SHARES IN ASTRAZENECA PLC

 

Further to the announcement of its irrevocable, non-discretionary share repurchase programme for the period 20 December 2011 to 2 February 2012, AstraZeneca PLC announced that under the terms of that programme it purchased for cancellation 471,646 ordinary shares of AstraZeneca PLC at a price of 3039 pence per share on 25 January 2012. Upon the cancellation of these shares, the number of shares in issue will be 1,285,000,223.

A C N Kemp

Company Secretary

26 January 2012

 

 

Tags:

About Us

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines. As a leader in gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease medicines, AstraZeneca generated global revenues of US $32.8 billion in 2009. For more information please visit: www.astrazeneca.com